At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 12, 2026 at 08:01 ET
Cogent Biosciences presented preclinical data for its novel JAK2 V617F mutant-selective inhibitor CGT1145 at the EHA Congress, highlighting >100x selectivity over JAK2 WT and JAK1/3 isoforms. The program remains on track for an IND submission in 2026. The data is early-stage and does not involve financial results or regulatory decisions, limiting near-term stock impact.
- CGT1145 is a potent, selective inhibitor of JAK2 V617F with >100x selectivity over JAK2 WT and JAK1/3 isoforms
- Preclinical data presented at the 2026 EHA Congress in Stockholm
- IND submission planned for 2026
- JAK2 V617F is the most prevalent mutation in BCR-ABL-negative MPNs, occurring in ~95% of polycythemia vera patients and ~50% of primary myelofibrosis / essential thrombocythemia patients
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access